Shopping Cart 0
Cart Subtotal
USD 0

IB Pharmaceuticals Inc (INNT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

IB Pharmaceuticals Inc (IB Pharmaceuticals), formerly Innovate Biopharmaceuticals Inc, is a clinical-stage biotechnology company that discovers and develops novel medicines for orphan and gastroenterological disorders. The company's pipeline includes INN-108 intended for inflammatory bowel disorders, ulcerative colitis and GI orphan disease; INN-202 intended for the treatment of celiac disease; INN-217 intended for nonalcoholic steatohepatitis; INN-289 intended for Crohn's disease; and INN-329 intended for magnetic resonance cholangiopancreatography. The company holds and operates its patents across the US, Japan and other countries. IB Pharmaceuticals is headquartered in Raleigh, North Carolina, the US.

IB Pharmaceuticals Inc (INNT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Innovate Biopharma Acquires Assets Related to RG-1068 from Repligen 11

Venture Financing 12

Innovate Biopharma Raises USD1.5 Million in Venture Financing 12

Innovate Biopharma Raises USD1.4 Million in Venture Financing 13

Innovate Biopharma Raises USD2.7 Million in Venture Financing 14

Partnerships 15

Innovate Biopharma Enters into Agreement with Amarex Clinical Research 15

IB Pharma Enters into Agreement with University of Virginia School of Medicine 16

Innovate Biopharma Enters into R&D Agreement with University of Maryland School of Medicine 17

Merger 18

Monster Digital Completes Reverse Merger Transaction with Innovate Biopharma 18

Licensing Agreements 20

Innovate Biopharm Enters into Licensing Agreement with Alba Therapeutics 20

Equity Offering 21

IB Pharma Plans to Raise up to USD175 Million in Public Offering of Shares 21

IB Pharma Plans to Raise Funds through Public Offering of Shares 22

IB Pharma Raises USD23.5 Million in Private Placement of Securities 23

Debt Offering 24

IB Pharma Raises USD4.8 Million in Private Placement of Debt Securities 24

IB Pharmaceuticals Inc-Key Competitors 25

IB Pharmaceuticals Inc-Key Employees 26

IB Pharmaceuticals Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

Aug 15, 2018: Innovate Biopharmaceuticals announces second quarter 2018 financial results 28

May 16, 2018: Innovate Biopharmaceuticals Reports First Quarter 2018 Key Financial and Corporate Highlights 29

Corporate Communications 30

Jun 13, 2018: Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D. 30

Mar 13, 2018: Innovate Biopharmaceuticals Names June Almenoff As Chief Operating Officer And Chief Medical Officer 31

Product Approvals 32

Sep 06, 2017: Innovate Biopharmas Pediatric Ulcerative Colitis Drug Granted FDA Orphan Designation 32

Jul 12, 2017: Innovate Biopharmaceuticals Submits Orphan Drug Application to FDA for Pediatric Ulcerative Colitis Indication 33

Clinical Trials 34

Feb 21, 2017: Innovate Biopharmaceuticals To Highlight Its Late-Stage Product Pipeline Targeting Celiac Disease And Ulcerative Colitis At The Cowen Healthcare Conference On March 6, 2017 34

Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on INN-108 Phase 2 Trial 35

Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on larazotide acetate (INN-202) 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

IB Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Innovate Biopharma Acquires Assets Related to RG-1068 from Repligen 11

Innovate Biopharma Raises USD1.5 Million in Venture Financing 12

Innovate Biopharma Raises USD1.4 Million in Venture Financing 13

Innovate Biopharma Raises USD2.7 Million in Venture Financing 14

Innovate Biopharma Enters into Agreement with Amarex Clinical Research 15

IB Pharma Enters into Agreement with University of Virginia School of Medicine 16

Innovate Biopharma Enters into R&D Agreement with University of Maryland School of Medicine 17

Monster Digital Completes Reverse Merger Transaction with Innovate Biopharma 18

Innovate Biopharm Enters into Licensing Agreement with Alba Therapeutics 20

IB Pharma Plans to Raise up to USD175 Million in Public Offering of Shares 21

IB Pharma Plans to Raise Funds through Public Offering of Shares 22

IB Pharma Raises USD23.5 Million in Private Placement of Securities 23

IB Pharma Raises USD4.8 Million in Private Placement of Debt Securities 24

IB Pharmaceuticals Inc, Key Competitors 25

IB Pharmaceuticals Inc, Key Employees 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

IB Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.